Vaxcyte Inc (PCVX) - Total Assets
Based on the latest financial reports, Vaxcyte Inc (PCVX) holds total assets worth $3.35 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Vaxcyte Inc's balance sheet to measure how much of total assets are equity-financed.
Vaxcyte Inc - Total Assets Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's total assets have evolved over time, based on quarterly financial data. Explore Vaxcyte Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Vaxcyte Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vaxcyte Inc's total assets of $3.35 Billion consist of 53.4% current assets and 46.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.7% |
| Accounts Receivable | $46.56 Million | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Vaxcyte Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxcyte Inc's current assets represent 53.4% of total assets in 2025, a decrease from 91.7% in 2017.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2025, down from 91.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Vaxcyte Inc Competitors by Total Assets
Key competitors of Vaxcyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Camurus AB
ST:CAMX
|
Sweden | Skr4.74 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $750.21 Million |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
Vaxcyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.49 | 17.70 | 7.41 |
| Quick Ratio | 7.49 | 17.70 | 7.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.57 Billion | $1.62 Billion | $260.83 Million |
Vaxcyte Inc - Advanced Valuation Insights
This section examines the relationship between Vaxcyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.14 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | -13.3% |
| Total Assets | $3.05 Billion |
| Market Capitalization | $6.85 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vaxcyte Inc's assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vaxcyte Inc's assets decreased by 13.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaxcyte Inc (2017–2025)
The table below shows the annual total assets of Vaxcyte Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.05 Billion | -13.25% |
| 2024-12-31 | $3.51 Billion | +149.40% |
| 2023-12-31 | $1.41 Billion | +39.93% |
| 2022-12-31 | $1.01 Billion | +210.23% |
| 2021-12-31 | $324.34 Million | -17.43% |
| 2020-12-31 | $392.83 Million | +497.93% |
| 2019-12-31 | $65.70 Million | -7.21% |
| 2018-12-31 | $70.80 Million | +78.65% |
| 2017-12-31 | $39.63 Million | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more